Sareum Regulatory News (SAR)

12 Jan 2007 07:00

Sareum Holdings PLC12 January 2007 For immediate release 12 January 2007 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Notice of Interim Results and R&D Update Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discoverybusiness, will be announcing its interim results for the six months ended 31December 2006 on Tuesday 6 February 2007. An analyst presentation will take place on the day at 10:00am at BuchananCommunications, 45 Moorfields, London EC2Y 9AE. In addition, on the same day, Sareum will be providing a research anddevelopment update for analysts at 10.30am also at the offices of BuchananCommunications. The R&D update will include the following presentations: What big pharma needs from biotech Professor David Tapolczay, Vice President, Technology Development, GlaxoSmithKline Levering biotech collaborations to attract big pharma licencing dealsDr Stephen Mayhew, Business Manager, Cancer Research Technology Sareum's in-house pipeline and licencing strategyDr John Reader, Founder and VP Chemistry, Sareum Copies of all the presentations will be available from 9.30am on 6 February 2007from www.sareum.co.uk. For further information please contact: Buchanan Communications 020 7466 5000Tim Anderson, Mary-Jane Johnson, Simon Potter About Sareum Holdings plc Sareum Holdings plc is a structure-based drug discovery business headquarteredin Cambridge, UK. The Company was formed in August 2003 to discover new drugsfor the treatment of cancer. Sareum's unique approach aims to halve the time ittakes to discover new drug candidates. A structure-based approach to drug discovery relies on knowledge of thethree-dimensional structure of the proteins that cause disease. Once thestructure is known, potential drugs are designed to 'lock-in' to the proteinwith the aim of reversing or arresting a disease's progression. Knowledge ofthe structure of the potential drugs and how they 'lock-in' to their targetprotein assists greatly in the development of high-quality drug candidates.Determining structure is a complex task and requires leading-edge equipment andexperienced staff. Sareum's approach to structure determination utilises itsproprietary protein expression platform in order to produce multiple recombinantproteins that accelerate structure determination using x-ray crystallography. Once the structure is determined, the Company's innovative fragment screeningplatform is used to identify novel chemical templates designed to interact withthe target protein. Sareum then uses its high-throughput medicinal chemistryplatform to rapidly optimise these molecules and develop the most promising intopotential drug candidates. Sareum aims to successfully deliver drug candidates for licensing to largerpharmaceutical companies at the pre-clinical or early clinical trials stage.This is funded by provision of its specialist drug discovery capabilities topartners in the pharmaceutical and biotechnology industries. Sareum joined the AIM market of the London Stock Exchange in October 2004 andtrades under the symbol SAR. For further information, please visitwww.sareum.co.uk This information is provided by RNS The company news service from the London Stock Exchange